CAS Registry Number raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-05 and is reviewed periodically as new material appears.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
=== Adrian Shephard === Adrian Shephard is the protagonist of Half-Life: Opposing Force. He is a 22-year old corporal in the United States Marine Corps (USMC) stationed at the fictional Santego Military Base in Arizona who is mysteriously transferred to the Hazardous Environment Combat Unit (HECU), a special USMC unit. Three months after his transfer, he is sent to the Black Mesa Research Facility (BMRF) to defeat the Xenian invasion and summarily execute all BMRF personnel. However, the Bell Boeing V-22 Osprey transporting him is hit by a Xenian energy blast and crashes; he is rescued by a group of Black Mesa scientists, and due to never making it to his designated landing zone, Shephard remains unaware of the secret orders to kill all BMRF employees. Making his way through the facility while being observed by the G-Man, he eventually comes across a thermonuclear weapon brought in by the Central Intelligence Agency and deactivates it, but the G-Man later reactivates it, leading to the eventual destruction of Black Mesa. In the end, the G-Man reveals that he has successfully argued for Shephard's life, detaining him in some unknown void. The G-Man expresses a degree of respect for Shephard, offering praise for his ability to "adapt and survive against all odds" which "rather reminds [the G-Man] of [himself]". Shephard is briefly mentioned in Half-Life: Blue Shift, where a HECU marine grumbles about taking over some of Shephard's squad's duties.
=== Earliest work === The study of hydrogen stable isotopes began with the discovery of deuterium by chemist Harold Urey. Even though the neutron was not realized until 1932, Urey began searching for "heavy hydrogen" in 1931. Urey and his colleague George Murphy calculated the redshift of heavy hydrogen from the Balmer series and observed very faint lines on a spectrographic study. To intensify the spectroscopic lines for publishable data, Murphy and Urey paired with Ferdinand Brickwedde and distilled a more concentrated pool of heavy hydrogen, now called deuterium. This work on hydrogen isotopes won Urey the 1934 Nobel Prize in Chemistry.
In September 2022, the ministry reported: "Repair work on the Cinesphere, pods, and bridges is proceeding on schedule this fall. Site servicing, including sewage, water, electrical, and gas, is expected to begin in the spring of 2023." Therme Canada's local partners are the Toronto International Film Festival (TIFF), Mississaugas of the Credit First Nation, and Black North Initiative. TIFF later 'paused' their relationship with Therme ahead of their 2023 festival. Other partners include AECON Group Inc., Diamond Schmitt, and Studio TLA. Strategy Corp is serving Therme Canada with strategy and communications. Swim Drink Fish Canada was a partner, but exited the partnership in the belief that the government's portion of the plan is "simply too opaque and controversial for us to support". Therme's plans have received strong public backlash, with the group Ontario Place for All leading the campaign against the development. Plans to develop the public space and existing beach by a for-profit private developer became a prominent 2023 election issue in Toronto. The mayoral campaign saw mayor Olivia Chow come out in opposition to the project. Later in 2023, she dropped her opposition to the project when the City and Government of Ontario reached an agreement for the transfer of the two Toronto freeways (Don Valley and Gardiner) to the province, saving the city an estimated $1.2 billion. The community group has continued its opposition, attempting to stop or slow down the project in the courts.
==== VEGF ==== Vascular endothelial growth factor (VEGF) has been demonstrated to be a major contributor to angiogenesis, increasing the number of capillaries in a given network. Initial in vitro studies demonstrated bovine capillary endothelial cells will proliferate and show signs of tube structures upon stimulation by VEGF and bFGF, although the results were more pronounced with VEGF. Upregulation of VEGF is a major component of the physiological response to exercise and its role in angiogenesis is suspected to be a possible treatment in vascular injuries. In vitro studies clearly demonstrate that VEGF is a potent stimulator of angiogenesis because, in the presence of this growth factor, plated endothelial cells will proliferate and migrate, eventually forming tube structures resembling capillaries. VEGF causes a massive signaling cascade in endothelial cells. Binding to VEGF receptor-2 (VEGFR-2) starts a tyrosine kinase signaling cascade that stimulates the production of factors that variously stimulate vessel permeability (eNOS, producing NO), proliferation/survival (bFGF), migration (ICAMs/VCAMs/MMPs) and finally differentiation into mature blood vessels. Mechanically, VEGF is upregulated with muscle contractions as a result of increased blood flow to affected areas. The increased flow also causes a large increase in the mRNA production of VEGF receptors 1 and 2. The increase in receptor production means muscle contractions could cause upregulation of the signaling cascade relating to angiogenesis.
The technique of balanced anesthetic has been applied widely with cats and dogs. When general anesthesia is used for cats and dogs, the most common method is inhalant agents because they are both easy to manage and the depth of anesthesia is predictable. The depth of anesthesia can be changed and recovered if some unexpected situation occurs during surgery. Although inhaled anesthetics will cause an unconscious state in which cats and dogs will not recall or perceive pain, the depth of anesthesia may not prevent the variety of reflex reactions to harmful stimuli during the operation. In order to prevent these reflex reactions, it may be required to increase the concentration of inhalant anesthetic agents; higher rates of inhalant administration are associated with higher cardiovascular and respiratory complications. Respiratory depression may result, especially in young patients and those with preexisting systemic disease. This is associated with increased morbidity and mortality. With the balanced anesthetic technique, the low concentration of inhalant anesthetic agents and other medicines used during the operation can alter the perception of painful stimuli. In other words, using balanced anesthetic techniques for cats and dogs can decrease the morbidity and mortality effectively. Therefore, in this situation, using balanced anesthetic techniques in cats and dogs is less risky for operation than using the general anesthesia.
Sources: en.wikipedia.org
Cricket in Hong Kong has been played since at least 1841. Like most cricketing nations, it was part of the British Empire. The national cricket team has been active since 1866, and the Hong Kong Cricket Association was granted associate membership of the International Cricket Council (ICC) in 1969. Hong Kong hosted the Hong Kong Cricket Sixes, an ICC-sanctioned event that features teams of six players in a six-over competition annually till 2012. The Hong Kong Cricket Team qualified for 2014 ICC World Twenty20 and caused a major upset by defeating hosts Bangladesh.
The MECP2 locus is X-linked and the disease-causing alleles are dominant. Due to its prevalence in females, it has been linked to male lethality, or to a predominant transmission with the paternal X chromosome; nevertheless, in rare cases some males can also be affected by Rett syndrome. Males with gene duplications of MECP-2 at the Xq28 locus are also at risk for recurrent infections & meningitis in infancy. Mutations in the MECP2 gene have also been identified in people with several other disorders affecting the central nervous system. For example, MECP2 mutations are associated with some cases of moderate to severe X-linked intellectual disability. Mutations in the gene have also been found in males with severe brain dysfunction (neonatal encephalopathy) who live only into early childhood. In addition, several people with features of both Rett syndrome and Angelman syndrome (a condition characterized by intellectual disability, problems with movement, and inappropriate laughter and excitability) have mutations in the MECP2 gene. Lastly, MECP2 mutations or changes in the gene's activity have been reported in some cases of autism (a developmental disorder that affects communication and social interaction). More recent studies reported genetic polymorphisms in the MeCP2 gene in patients with systemic lupus erythematosus (SLE). SLE is a systemic autoimmune disease that can affect multiple organs. MeCP2 polymorphisms have been reported so far in European-derived and Asian lupus patients.
== Regulation == A number of sporting authorities and countries have banned or heavily restricted the use of methylhexanamine as a dietary supplement, due to serious concerns about its safety. These countries include Australia, Brazil, Canada, Finland, New Zealand, Sweden, Switzerland, the United Kingdom, and the United States.
== External links == Actinium at The Periodic Table of Videos (University of Nottingham) NLM Hazardous Substances Databank – Actinium, Radioactive Actinium in Kirby, H. W.; Morss, L. R. (2006). Morss; Edelstein, Norman M.; Fuger, Jean (eds.). The Chemistry of the Actinide and Transactinide Elements (3rd ed.). Dordrecht, The Netherlands: Springer. ISBN 978-1-4020-3555-5.
Sources: en.wikipedia.org
=== Crustaceans === Acartia tonsa dana, cosmopolitan calanoid copepod (2019) Cherax quadricarinatus, Red claw crayfish (2020) Daphnia pulex, water flea (2007) Eulimnadia texana, Clam Shrimp (2018) Macrobrachium nipponense, oriental river prawn (2021) Neocaridina denticulata, shrimp (2014) Parhyale hawaiensis, amphipod (2016) Pollicipes pollicipes, Gooseneck barnacle (2022) Portunus trituberculatus, swimming crab (2020) Procambarus virginalis, marbled crayfish (2018) Sphaeroma terebrans, a wood-boring isopod (2019) Tigriopus kingsejongensis, antarctic-endemic copepod (2017)
== Notable ascents == 1953 2nd ascent Yosemite Point Buttress. (With Royal Robbins) 1953 2nd ascent North Face Sentinel Rock. (With Royal Robbins and Don Wilson) 1953 Palisades Traverse Thunderbolt Peak to Mount Sill via North Palisade. (With Gary Hemming) 1954 5th ascent Lost Arrow Spire. (With Wayne Merry) 1955 3rd ascent Lost Arrow Chimney. (With Charles Wilts and Don Wilson) 1956 1st ascent Spider Rock, Canyon de Chelly National Monument, AZ, USA, March 30. (With Mark Powell and Don Wilson) 1956 1st ascent East Buttress of Middle Cathedral Rock, Yosemite National Park, CA, USA, June 16. (With Mark Powell and Don Wilson) 1956 5th ascent Castle Rock Spire. (With Charles Wilts) 1956 1st ascent Cleopatra's Needle, Valley of the Thundering Water, NM, USA, September 6. (With Mark Powell and Don Wilson) 1957 1st ascent The Step, Tahquitz Idyllwild, CA, USA, May 18. (With Royal Robbins) 1957 1st ascent Totem Pole, Monument Valley, AZ, USA. June 13. (With Bill Feuerer, Mark Powell, and Don Wilson) 1957 1st ascent Northwest Face of Half Dome, Yosemite, CA, USA, June 23–27. First grade VI climb in America. (With Mike Sherrick and Royal Robbins)
Enzyme structures may also contain allosteric sites where the binding of a small molecule causes a conformational change that increases or decreases activity. A small number of RNA-based biological catalysts called ribozymes exist, which again can act alone or in complex with proteins. The most common of these is the ribosome which is a complex of protein and catalytic RNA components.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.